Stoke Therapeutics Inc (STOK) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access STOK Annual Balance Sheets →
Balance sheet performance over multiple periods helps investors evaluate the financial resilience of Stoke Therapeutics Inc.
Quarterly Report, GAAP in USD millions
ITEM
(Mar 31 2026)
(Dec 31 2025) (Sep 30 2025) (Jun 30 2025) (Mar 31 2025)
Assets
Cash & cash equivalent155.66
Available-for-sale Securities, Debt Securities, Current MA187.89
Cash & Short-term Investments342.00
Accounts receivable4.45
Interest Receivable, Current1.69
Other Current Assets6.88
Prepaid Expense, Current AS10.12
Total Current Assets366.68
Equipment/Property/Plant Net3.40
Long-term investments67.48
Other Assets, Noncurrent5.72
Restricted Cash Current-
Restricted Cash Noncurrent3.23
Total Assets443.28
Liabilities
Accounts Payable, Current AC6.84
Deferred Revenue, Current DE10.07
Total Current Liabilities40.81
Total Long-term Debt0.00
Deferred Revenue, Noncurrent DE6.60
Other liabilities, Noncurrent24.89
Accrued And Other Current Liabilities23.90
Total Liabilities48.40
Stockholders' Equity
Common Stock Value0.01
Additional Paid In Capital Common Stock942.70
Retained Earnings / Accumulated Deficit-547.72
Other Equity-0.11
Common Stockholder's Equity394.88
Total Stockholder's Equity394.88
Liabilities & Stockholder's Equity443.28
4 historic quarters locked

Sign in to unlock the full Stoke Therapeutics Inc balance sheet history.

About Stoke Therapeutics Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001193125-26-330557

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.